Article
Pediatrics
Jennifer C. C. deBruyn, Kevan Jacobson, Wael El-Matary, Eytan Wine, Matthew W. Carroll, Caitlin Goedhart, Remo Panaccione, Iwona T. Wrobel, Hien Q. Huynh
Summary: The study evaluated the relationship between serum infliximab concentrations during induction and short-term clinical remission in children with ulcerative colitis. Higher infliximab concentrations prior to the second dose were associated with week 8 clinical remission. Young age and low body weight impact infliximab concentration, prompting the need for proactive adjustment in pediatric patients with ulcerative colitis.
FRONTIERS IN PEDIATRICS
(2021)
Article
Gastroenterology & Hepatology
Ryusuke Nambu, Takahiro Kudo, Nao Tachibana, Hirotaka Shimizu, Tatsuki Mizuochi, Sawako Kato, Mikihiro Inoue, Hideki Kumagai, Takashi Ishige, Reiko Kunisaki, Atsuko Noguchi, Toshifumi Yodoshi, Shin-Ichiro Hagiwara, Shigeo Nishimata, Fumihiko Kakuta, Takeshi Saito, Itaru Iwama, Yuri Hirano, Toshiaki Shimizu, Katsuhiro Arai
Summary: In pediatric UC patients, approximately 50% underwent colectomy during a 2-year interval following IFX failure. Prognosis after IFX failure appeared to improve with availability of new biologic agents and small-molecule drugs in mid-2018.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Edward V. Loftus, Severine Vermeire, Brian G. Feagan, Franck-Olivier Le Brun, Alessandra Oortwijn, Ulrik Moerch, William J. Sandborn, Toshifumi Hibi
Summary: In patients with ulcerative colitis, the study found that 200 mg of filgotinib can reduce the use of corticosteroids and maintain corticosteroid-free clinical remission. Moreover, compared to other medications, filgotinib demonstrated better outcomes in patients who had not previously used biologic agents.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Pharmacology & Pharmacy
Alix Demaris, Ella S. K. Widigson, Johan F. K. F. Ilvemark, Casper Steenholdt, Jakob B. Seidelin, Wilhelm Huisinga, Robin Michelet, Linda B. S. Aulin, Charlotte Kloft
Summary: This review aims to analyze the population PK models of infliximab (IFX) in patients with ulcerative colitis (UC) and acute severe UC (ASUC), and assess the impact of disease activity on IFX PK. The results showed that there are still many gaps in the current research, such as a limited number of models specifically developed for UC patients, a lack of studies on severe UC patients, and a lack of evaluation of predictive performance for the models. Therefore, more comprehensive research and adequate reporting and evaluation of the models are needed for clinical application.
Article
Gastroenterology & Hepatology
Miikka Hoyhtya, Katri Korpela, Schahzad Saqib, Sofia Junkkari, Eija Nissila, Anne Nikkonen, Evgenia Dikareva, Anne Salonen, Willem M. de Vos, Kaija-Leena Kolho
Summary: This study aimed to investigate the absolute abundances of gut microbiota in relation to the response to induction therapy with infliximab in pediatric inflammatory bowel disease. The results showed that the treatment responsive group had a higher absolute abundance of Bifidobacteriales and a lower absolute abundance of Actinomycetales compared to the nonresponders. However, the level of inflammation according to fecal calprotectin showed no statistically significant association with the absolute abundances of fecal microbiota. The results on relative abundances differed from the absolute abundances.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Medicine, General & Internal
Benjamin L. Gordon, Robert Battat
Summary: Therapeutic drug monitoring (TDM) is a useful strategy in ulcerative colitis (UC), particularly in acute severe UC (ASUC). While there is limited data available for the use of TDM of infliximab in ASUC, observational data suggest that higher serum infliximab concentrations and lower clearance are associated with better clinical outcomes and decreased rates of colectomy. However, more studies are needed to evaluate optimal dosing and TDM targets in this population.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Andreas Blesl, Philipp Wurm, Silvio Waschina, Hans Peter Groechenig, Gottfried Novacek, Christian Primas, Walter Reinisch, Maximilian Kutschera, Constanze Illiasch, Barbara Hennlich, Pius Steiner, Robert Koch, Wolfgang Tillinger, Thomas Haas, Gerhard Reicht, Andreas Mayer, Othmar Ludwiczek, Wolfgang Miehsler, Karin Steidl, Lukas Binder, Simon Reider, Christina Watschinger, Stefan Fuerst, Patrizia Kump, Alexander Moschen, Konrad Aden, Gregor Gorkiewicz, Christoph Hoegenauer, Austrian IBD Study Grp ATISG
Summary: This study examined the association between fecal microbial composition and response to systemic corticosteroids in patients with active ulcerative colitis. It found that baseline microbial diversity and composition could not predict response to corticosteroids, but responders had significant changes in microbial diversity and composition after 4 weeks of treatment.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Robert Gilmore, Wei Lian Tan, Richard Fernandes, Yoon-Kyo An, Jakob Begun
Summary: This study found that upadacitinib may be a safe and effective salvage therapy for patients with steroid-refractory acute severe ulcerative colitis who have previously failed to respond to infliximab therapy. Prospective studies are needed to determine the safety and efficacy of upadacitinib use in this setting before routine use can be recommended.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Neeraj Narula, Emily C. L. Wong, John K. Marshall, Jean-Frederic Colombel, Parambir S. Dulai, Walter Reinisch
Summary: For patients with moderate to severe biologic naive UC, infliximab and vedolizumab have similar efficacy in improving clinical symptoms, but infliximab has higher rates of corticosteroid-free clinical remission (CR) and endoscopic remission (ER) after 1 year of treatment.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Stefan Schreiber, Shomron Ben-Horin, Jaroslaw Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Pukitis, Marek Horynski, Katalin Farkas, Jaroslaw Kierkus, Maciej Kowalski, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Mi Rim Kim, Seul Gi Lee, Byong Duk Ye, Walter Reinisch
Summary: This study demonstrated the pharmacokinetic noninferiority of CT-P13 SC to CT-P13 IV, with comparable clinical remission rates between the two formulations.
Article
Gastroenterology & Hepatology
Ami Kawamoto, Toshimitsu Fujii, Ryuji Mitani, Yasuhiro Suzuki, Tsunehito Yauchi, Ryuichi Okamoto
Summary: This article reports for the first time the serum drug levels and long-term health status of the child of a patient treated with CT-P13 throughout her pregnancy.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Medical Laboratory Technology
Yiyi Xie, Tingting Zhuang, Ying Ping, Yingzhi Zhang, Xuchu Wang, Pan Yu, Xiuzhi Duan
Summary: It has been found that high levels of Systemic immune-inflammation index (SII) are associated with poor outcomes in ulcerative colitis (UC) patients. Our study confirmed that SII levels were significantly elevated in UC patients and closely correlated with disease activity, showing high diagnostic capacity for active UC.
CLINICA CHIMICA ACTA
(2021)
Article
Gastroenterology & Hepatology
Gaurav Syal, Lori Robbins, Amir Kashani, Nirupama Bonthala, Edward Feldman, Phillip Fleshner, Eric Vasiliauskas, Dermot McGovern, Christina Ha, Stephan Targan, Gil Y. Melmed
Summary: Serum albumin and band neutrophil percentage are independent predictors of failure of infliximab rescue therapy in patients with acute severe ulcerative colitis. The combination of serum albumin <= 2.5 g/dl and band neutrophil count >= 13% has a 100% positive predictive value for 90-day colectomy.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Article
Pediatrics
Shai Stewart, Kayla B. Briggs, Charlene Dekonenko, James A. Fraser, Wendy Jo Svetanoff, Tolulope A. Oyetunji, Julie A. Bass, Shawn D. St Peter
Summary: This study reviewed the experience and outcomes of pediatric severe colitis patients who underwent inpatient rescue treatment with infliximab. The results showed a low success rate of rescue therapy with infliximab, with a higher number of patients requiring colectomy.
JOURNAL OF PEDIATRIC SURGERY
(2023)
Article
Gastroenterology & Hepatology
Robert Gilmore, Patrick Hilley, Ashish Srinivasan, Matthew Choy, Peter De Cruz
Summary: This study found that high-dose tofacitinib may have a role as salvage therapy in patients with steroid-refractory ASUC.
JOURNAL OF CROHNS & COLITIS
(2022)